Continue to site >
Trending ETFs

Royalty Pharma plc

Stock (NASDAQ)
RPRX
Payout Change
Pending
Price as of:
$24.92 +0.64 +0%
Dividend (Fwd)
$0.84
Yield (Fwd)
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
3.37%
RPRX: NASDAQ (Stock)

Royalty Pharma plc

Payout Change
Pending
Price as of:
$24.92 +0.64 +0%
Dividend (Fwd)
$0.84
Yield (Fwd)
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
3.37%
RPRX: NASDAQ (Stock)

Royalty Pharma plc

$24.92 +0%
Dividend (Fwd)
$0.84
Yield (Fwd)
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
3.37%
Payout Change
Pending
Analysis

Name

As of 12/20/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

  & DIV

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

Royalty Pharma plc

RPRX | stock

$24.92

2.64%

$14.3 B

3.37%

$0.84

-

Dividend Data
Stock Data
Avg Price Recovery
9.8 Days
Best dividend capture stocks in Dec
Payout Ratio (FWD)
Fwd Payout Ratio is used to examine if a company’s earnings can support the current dividend payment amount. It divides the Forward Annualized Dividend by FY1 EPS. Click here to learn more.
19.17%
Years of Dividend Increase
Consecutive Years of Dividend Increase is the number of years in a row in which there has been at least one payout increase and no payout decreases.
4 yrs
Dividend Frequency
Quarterly
Health Care Avg Yield
1.58%
5 best health care dividend stocks
Market Cap
$14.305 B
Day’s Range
$24.32 - $25.0
Volume
7,574,600
52 Wk Low/High
$24.05 - $31.66
Percent off 52 Wk High
-21.29%
FY1 PE
5.69x
FY1 EPS / Growth
$4.38 / 10.36%

Name

As of 12/20/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

  & DIV

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

Royalty Pharma plc

RPRX | stock

$24.92

2.64%

$14.3 B

3.37%

$0.84

-

Ratings - RPRX

Dividend Safety

A+

20% payout ratio (sector 37%). Stable.

Yield Attractiveness

A

3.46% forward dividend yield. Top 30%.

Returns Risk

A+

0.5 beta (5Y monthly). Diversifier.

Returns Potential

A+

72% price target upside from sell-side analysts. Top 20%.

Quant Recommendation - RPRX

Maximize Income Goal

Target

Yields of 7-9%

Horizon

Short

Risk

Moderate-to-high

Retirement Income Goal

Target

Blend low volatility & yield

Horizon

Long

Risk

Low

Monthly Income Goal

Regular payouts for RPRX are paid quarterly. Recommendation not provided. See Best Monthly Dividend Stocks Model Portfolio for our top monthly income ideas.

Growth Goal

Target

Market-beating returns

Horizon

Long

Risk

Moderate

Income & Growth Goal

Target

Blend yield & returns

Horizon

Moderate

Risk

Moderate

Sector Income & Growth Goal

Target

Blend yield & returns in the Health Care sector

Horizon

Long

Risk

Moderate-to-high

RPRX Payout History (Paid, Declared and Estimated)

Declared
Paid
Estimated
Year Calendar Year Payout (USD) Calendar Year Payout Growth (USD) Pay Date Declared Date Ex-dividend Date Payout Amount (USD) Qualified Dividend? Payout Type Frequency Days Taken For Stock Price To Recover Yield on Cost
2026e - -
2026-12-15
2026-10-16 2026-11-16 $0.2100 Qualified Regular Quarterly - -
2026-09-15
2026-07-17 2026-08-17 $0.2100 Qualified Regular Quarterly - -
2026-06-15
2026-04-17 2026-05-18 $0.2100 Qualified Regular Quarterly - -
2026-03-13
2026-01-09 2026-02-13 $0.2100 Qualified Regular Quarterly - -
2025e - -
2025-12-15
2025-10-16 2025-11-14 $0.2100 Qualified Regular Quarterly - -
2025-09-15
2025-07-17 2025-08-15 $0.2100 Qualified Regular Quarterly - -
2025-06-13
2025-04-17 2025-05-16 $0.2100 Qualified Regular Quarterly - -
2025-03-14
2025-01-09 2025-02-14 $0.2100 Qualified Regular Quarterly - -
2024e - -
2024-12-10
2024-10-11 2024-11-15 $0.2100 Qualified Regular Quarterly - 0.82%
2024-09-13
2024-07-17 2024-08-16 $0.2100 Qualified Regular Quarterly - 0.77%
2024-06-14
2024-04-17 2024-05-16 $0.2100 Qualified Regular Quarterly - 0.75%
2024-03-15
2024-01-19 2024-02-15 $0.2100 Qualified Regular Quarterly - 0.70%

RPRX Dividend Growth CAGR

Dividend Capture Strategy for RPRX

Dividend capture strategy is based on RPRX’s historical data. Past performance is no guarantee of future results.

Step 1: Buy RPRX shares 1 day before the ex-dividend date

Purchase Date

Feb 13, 2025

Upcoming Ex-Dividend Date

Feb 14, 2025

Step 2: SEll RPRX shares when price recovers

Sell Date (Estimate)

Feb 24, 2025

Avg Price Recovery

9.8 Days

Avg yield on cost

0.55%

See Full History

News & Research

News

Research

Sorry, there are no articles available for this stock.

Company Profile

Company Overview

Exchanges: NASDAQ

Sector: Health Care

Industry: Biotech Pharma

No company description available.

Related Companies

Company Name

Price

Change

% Change

Ab Science

$0.89

$0.00

0.000%

Assembly Biosciences, Inc.

$15.21

-$0.60

-3.795%

ACADIA PHARMACEUTICALS INC

$16.87

$0.14

0.837%

ASP Isotopes Inc.

$4.89

$0.54

12.414%

Alterola Biotech, Inc.

$0.00

-$0.01

-100.000%

ABVC BioPharma, Inc.

$0.52

$0.00

0.000%

Arrowhead Pharmaceuticals, Inc.

$19.45

-$0.05

-0.256%

Aptose Biosciences Inc.

$0.28

$0.11

64.706%

APTEVO THERAPEUTICS INC.

$4.41

-$0.12

-2.649%

© 2020&nbsp Market data provided is at least 15-minutes delayed and hosted by Barchart Solutions.

Information is provided ‘as is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use, please see disclaimer